A systematic analysis to determine the frequency of obesity, high blood pressure (HBP) and diabetes mellitus (DM) for high-risk breast cancer(BC) patients (pts) BRCA1/2 (B1, B2) mutated vs pts without B1/B2 mutations.
This prospective study evaluated 44 pts with B1/B2 pathogenic mutations vs 191 non-mutated high-risk BC pts, tested in IOCN during 2015-2016. Inclusion criteria: triple negative BC
Out of 44 BC pts, 29 (11.6%) pts B1 mutated, 15 (6%) pts B2 and 191 pts had no B1/B2 deleterious mutations. The median age at diagnosis was 39 yo (28-74) in the B1/B2 mutated group and 37 yo (23- 80) for pts without B1/B2 mutations, p = 0.1122. In B1/B2 mutated pts, 22(50%) had normal weight, 13(29.54%) were overweight and 9 (20.45%) were obese. In the non-mutated group 4 (2.11%) pts were underweight, 114 (60.31%) had normal weight, 49(25.92%) pts were overweight and 22(11.64) were obese, p = 0.0742. Regarding HBP, in the B1/B2 mutated, 9 (20.45%) pts presented the condition in their personal history, while 35(79.54%) had no history of HBP, and in the non-mutated group, 15 (7.98%) pts related history of HBP and 173 (92.02%) pts did not have HBP, p = 0.0246, statistically significant when comparing the subgroups. In the B1/B2 mutated group, only 1 (2,27) patient related DM as comorbidities, while 43(97.23%) pts did not present the disease vs 5(2. 80%) pts with DM and 174 (97.20%) pts who did not have DM in the non- mutated group, p = 0.9999.
This prospective study represents the first analysis of conditions such as obesity, HBP and DM in Romanian high-risk BC pts. Our results indicate that HBP is a more frequent comorbidity in Romanian high risk BC B1/B2 mutated pts when compared with pts without B1/B2 deleterious mutations.
Clinical trial identification
Legal entity responsible for the study
International Innovation Grant-Conquer Cancer Foundation
All authors have declared no conflicts of interest.